Cagrilintide Providers in Florida
1 provider offering Cagrilintide in Florida
About Cagrilintide
Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells that promotes satiety and slows gastric emptying. Developed by Novo Nordisk, cagrilintide is being studied both as a standalone weight-management therapy and as the amylin component of the CagriSema combination. As monotherapy in Phase 2 trials, cagrilintide 2.4 mg weekly produced approximately 10.8% mean weight loss over 26 weeks — competitive with older GLP-1 agents.
Learn more about CagrilintideS
Comparing care options here? For cost-specific research, see Cagrilintide pricing in Florida.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.